Genfit

Genfit
Name	Genfit
Type	Public
Industry	Biotechnology
Founded	1999
Founder	Pascal Prigent
Headquarters	Lille, France
Key people	Jean-François Mouney, Pascal Prigent
Products	Therapeutics for liver diseases

Genfit

Genfit is a French biotechnology company focused on metabolic, inflammatory, and fibrotic liver diseases. The company develops small molecules and biologics and engages with regulatory agencies such as the European Medicines Agency, Food and Drug Administration, and National Institute for Health and Care Excellence on clinical development and market access. Genfit has partnered with pharmaceutical firms, academic centers, and contract research organizations including Servier, Ipsen, Sanofi, Eli Lilly and Company, and Charles River Laboratories to advance its pipeline.

Company overview

Genfit is headquartered in Lille and listed on the Euronext Paris exchange. The company integrates discovery platforms, translational research, and late-stage clinical development with collaborations involving universities such as Institut Pasteur, University of Cambridge, Harvard Medical School, and research institutes like Inserm and CNRS. Corporate governance has included executives and board members with backgrounds at Sanofi, Roche, Novartis, GlaxoSmithKline, and advisory ties to regulatory experts from the European Commission and advisory bodies like HAS (France). Genfit’s operational footprint spans France, the United States, and partnering networks in Belgium, Germany, and Switzerland.

History

Founded in 1999 by Pascal Prigent, Genfit's early work focused on nuclear receptor biology and metabolic regulation, building on scientific foundations from laboratories linked to CNRS and Université de Lille. The firm expanded through strategic alliances, equity financings on Euronext, and participation in translational consortia involving European Commission research programs and the Wellcome Trust. Leadership changes and board appointments have included executives with experience at Johnson & Johnson, Pfizer, and AstraZeneca. Genfit’s historical milestones include discovery-stage work in bile acid and peroxisome proliferator-activated receptor pathways and subsequent clinical development programs in liver disease.

Research and development

Genfit’s R&D centers on hepatic pathophysiology, including steatosis, inflammation, and fibrosis, leveraging knowledge from investigators at Mount Sinai, Massachusetts General Hospital, Imperial College London, and Mayo Clinic. The company employs preclinical models common to translational hepatology used by groups at Wake Forest School of Medicine and utilizes biomarkers and noninvasive diagnostics developed alongside teams at University of California, San Diego and Karolinska Institutet. R&D collaborations include partnerships with contract research organizations like ICON PLC and technology firms such as Illumina for genomic assays and Roche Diagnostics for biomarker platforms. Genfit has filed intellectual property in jurisdictions including United States Patent and Trademark Office and European Patent Office.

Products and pipeline

Genfit’s pipeline historically featured investigational small molecules targeting liver disease and metabolic disorders, with programs addressing nonalcoholic steatohepatitis and cholestatic conditions. Clinical candidates were developed with input from hepatology centers at Cleveland Clinic, Johns Hopkins Medicine, Baylor College of Medicine, and University College London Hospitals. The product portfolio and exploratory assets have been positioned for regulatory interactions with EMA and FDA and for market access discussions with payers such as NICE and health technology assessment bodies across France, Germany, and Spain.

Clinical trials

Genfit conducted randomized, controlled trials in multi-center settings involving sites across Europe and North America, coordinating trial management with contract research organizations familiar to sponsors like Quintiles (IQVIA), PPD, Inc., and Covance. Key endpoints in studies reflected standards set by hepatology consortia and guidance from scientific meetings such as the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Trials included biomarker development parallel to imaging modalities used by Mayo Clinic and histological endpoints standard in trials performed at UCSF Medical Center and Mount Sinai. Results presentations were made at conferences including AASLD Liver Meeting, EASL Congress, and publications in journals comparable to The Lancet, New England Journal of Medicine, and Journal of Hepatology.

Financial performance and ownership

Genfit has raised capital through public offerings on Euronext Paris, private placements, and partnerships with pharmaceutical firms and venture investors including Sofinnova Partners and corporate venture arms of Sanofi-affiliated funds. Shareholding has included institutional investors common to European biotech such as AXA Investment Managers, Amundi, and specialist healthcare funds. Financial reporting followed standards required by Autorité des marchés financiers and involved audits by major firms comparable to Deloitte and PwC. Market capitalization and revenue streams were influenced by clinical readouts, licensing deals, and potential milestone payments from collaborators.

Controversies and legal issues

Genfit’s development programs and corporate actions have attracted scrutiny in contexts familiar to biotechnology companies, including regulatory interactions with EMA and FDA, shareholder disputes encountered in public companies such as those listed on Euronext, and intellectual property challenges overseen by the European Patent Office and US District Court venues. Media coverage in outlets like Les Échos, Le Monde, Financial Times, and Reuters reported on trial outcomes, strategic decisions, and governance debates that paralleled controversies faced by peers in the biotechnology sector. Legal proceedings and licensing negotiations involved law firms experienced in life sciences matters and dispute resolution in commercial courts in Paris and arbitration forums often used in cross-border pharmaceutical agreements.

Category:Biotechnology companies of France